Aducanumab—Hope or Disappointment for Alzheimer’s Disease
Open accessAbstract
In June 2021, the world was informed about a new drug for Alzheimer’s disease approved by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest AD treatment. The activity of the drug is targeted towards amyloid β, which is considered one of the main causes of Alzheimer’s disease. Clinical trials have revealed time- and dose-dependent activity towards Aβ reduction, as well as cognition improvement. Biogen, the company responsible for conducting research and introducing the drug to the market, presents the drug as a solution to cognitive impairment, but its limitations, costs, and side effects are controversial. The framework of the paper focuses on the mechanism of aducanumab’s action along with the positive and negative sides of the therapy. The review presents the basis of the amyloid hypothesis that is the cornerstone of therapy, as well as the latest information about aducanumab, its mechanism of action, and the possibility of the use of the drug.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Aducanumab is the first disease-modifying medication for AD, a recombinant monoclonal antibody targeting amyloid beta specifically, and functions by lowering amyloid deposits or brain plaques.
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [131]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]
Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., Wessels, S. R., & Armstrong, M. J. (2022) · Neurology · doi:10.1212/wnl.0000000000200176 · Cited by 40 · see citing works
RetractedContinuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200 · see citing works
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336 · see citing works
Development of therapeutic antibodies for the treatment of diseases
Lu, R., Hwang, Y., Liu, I.-J., Lee, C., Tsai, H.-Z., Li, H., & Wu, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,106 · see citing works
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 2× · see citing works
“• Individual differences exist in the ability of inflammatory cells to effectively clear senile plaques in the brain [51].”
Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens
Kung, P. C., Goldstein, G., Reinherz, E. L., & Schlossman, S. F. (1979) · Science · doi:10.1126/science.314668 · Cited by 1,453 · see citing works
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1× · see citing works
“• Lowering amyloid levels through immunotherapy against the amyloid caused harm to the recipients, including neuroinflammation [52].”
Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism
Cohen, S. I. A., Linse, S. S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., Otzen, D. E., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218402110 · Cited by 1,410 · see citing works
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367 · see citing works
Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease
Wang, X., Wang, W., Li, L., Perry, G., Lee, H.-G., & Zhu, X. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.10.015 · Cited by 1,357 · see citing works
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 815 · see citing works
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works
The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
Sengupta, U., Nilson, A. N., & Kayed, R. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.035 · Cited by 740 · see citing works
Rabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674 · see citing works
Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619 · see citing works
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568 · see citing works
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567 · see citing works
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · see citing works
Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment
Douaud, G., Refsum, H., de Jager, C. A., Jacoby, R. J., Nichols, T. E., Smith, S. M., & Smith, A. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301816110 · Cited by 515 · see citing works
The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive ImpairmentPreprint
Tarawneh, R. M., & Holtzman, D. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006148 · Cited by 474 · see citing works
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · see citing works
Monoclonal antibody therapeutics: history and future
Buss, N. A. P. S., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 436 · see citing works
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 364 · see citing works
Behl, T., Kaur, D., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Andronie-Cioară, F. L., Toma, M. M., BUNGAU, S. G., & Bumbu, A. G. (2021) · Molecules · doi:10.3390/molecules26123724 · Cited by 333 · see citing works
Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimer’s disease
Styr, B., & Slutsky, I. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0080-x · Cited by 314 · see citing works
Brain microbleeds and Alzheimer’s disease: innocent observation or key player?
Cordonnier, C., & van der Flier, W. M. (2011) · Brain · doi:10.1093/brain/awq321 · Cited by 310 · see citing works
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works
Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls
Esparza, T. J., Zhao, H., Cirrito, J. R., Cairns, N. J., Bateman, R. J., Holtzman, D. M., & Brody, D. L. (2012) · Annals of Neurology · doi:10.1002/ana.23748 · Cited by 304 · see citing works
Logovinsky, V., Satlin, A., Lai, R. Y. K., Swanson, C. J., Kaplow, J. M., Osswald, G., Basun, H., & Lannfelt, L. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0181-2 · Cited by 289 · see citing works
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology
Rahman, M. M., & Lendel, C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00465-0 · Cited by 245 · see citing works
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239 · see citing works
Alzheimer Disease, a Multifactorial Disorder Seeking Multi-therapies
Iqbal, K., & Grundke-Iqbal, I. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.04.006 · Cited by 231 · see citing works
Takeuchi, A., Irizarry, M. C., Duff, K., Saido, T. C., Hsiao Ashe, K., Hasegawa, M., Mann, D. M. A., Hyman, B. T., & Iwatsubo, T. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64544-0 · Cited by 229 · see citing works
Distinct Early Folding and Aggregation Properties of Alzheimer Amyloid-β Peptides Aβ40 and Aβ42
Chen, Y., & Glabe, C. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602363200 · Cited by 214 · see citing works
Alzheimer disease and aducanumab: adjusting our approach
Selkoe, D. J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0205-1 · Cited by 208 · see citing works
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies
Linse, S. S., Scheidt, T., Bernfur, K., Vendruscolo, M., Dobson, C. M., Cohen, S. I. A., Šileikis, E., Lundqvist, M., Qian, F., O’Malley, T. T., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0505-6 · Cited by 201 · see citing works
Immunotherapy for Alzheimer’s disease: hoops and hurdles
Lemere, C. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-36 · Cited by 196 · see citing works
Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy
Dierksen, G. A., Skehan, M. E., Khan, M. A., Jeng, J., Nandigam, R. N. K., Becker, J. A., Kumar, A., Neal, K. L., Betensky, R. A., Frosch, M. P., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22099 · Cited by 195 · see citing works
Raha, A. A., Vaishnav, R., Friedland, R. P., Bomford, A. B., & Raha‐Chowdhury, R. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-55 · Cited by 179 · see citing works
Sarroukh, R., Cerf, E., Derclaye, S., Dufrêne, Y. F., Goormaghtigh, E., Ruysschaert, J., & Raussens, V. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0529-x · Cited by 150 · see citing works
Pericapillary Haem-Rich Deposits: Evidence for Microhaemorrhages in Aging Human Cerebral Cortex
Cullen, K. M., Kócsi, Z., & Stone, J. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600155 · Cited by 137 · see citing works
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135 · see citing works
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127 · see citing works
Sama, D. M., & Norris, C. M. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.05.008 · Cited by 126 · see citing works
Role of Calcium Homeostasis in Alzheimer’s Disease
Ge, M., Zhang, J., Chen, S., Huang, Y., Chen, W., He, L., & Zhang, Y. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s350939 · Cited by 124 · see citing works
Bressler, S. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.10.1589 · Cited by 117 · see citing works
Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice
Kastanenka, K. V., Bussière, T., Shakerdge, N. B., Qian, F., Weinreb, P. H., Rhodes, K., & Bacskai, B. J. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2080-16.2016 · Cited by 112 · see citing works
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2017) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.03.019 · Cited by 104 · see citing works
Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology
Berson, A., Knobloch, M., Hanan, M., Diamant, S., Sharoni, M. A., Schuppli, D., Geyer, B. C., Ravid, R., Mor, T. S., Nitsch, R. M., et al. (2007) · Brain · doi:10.1093/brain/awm276 · Cited by 104 · see citing works
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104 · see citing works
Wojtunik‐Kulesza, K. A., Oniszczuk, A., & Waksmundzka‐Hajnos, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.140 · Cited by 102 · see citing works
Self-citationFolch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2015) · Neurología · doi:10.1016/j.nrl.2015.03.012 · Cited by 98 · see citing works
Guan, P.-P., Cao, L., & Wang, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115900 · Cited by 96 · see citing works
Role of Calcium Homeostasis in Alzheimer’s Disease
Ge, M., Zhang, J., Chen, S., Huang, Y., Chen, W., He, L., & Zhang, Y. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 86 · see citing works
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 73 · see citing works
An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70 · see citing works
Peptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 69 · see citing works
Monoclonal Antibodies as Neurological Therapeutics
Gklinos, P., Papadopoulou, M., Stanulović, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 62 · see citing works
Rees, T. M., Berson, A., Sklan, E. H., Younkin, L. H., Younkin, S. G., Brimijoin, S., & Soreq, H. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367847 · Cited by 60 · see citing works
A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease
Sepulveda-Falla, D., Chavez-Gutierrez, L., Portelius, E., Vélez, J. I., Dujardin, S., Barrera-Ocampo, A., Dinkel, F., Hagel, C., Puig, B., Mastronardi, C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02249-0 · Cited by 54 · see citing works
Amyloid-Beta Mediates Homeostatic Synaptic Plasticity
Galanis, C., Fellenz, M., Becker, D., Bold, C. S., Lichtenthaler, S. F., Müller, U., Deller, T., & Vlachos, A. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.1820-20.2021 · Cited by 53 · see citing works
“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50 · see citing works
The Problem of Aducanumab for the Treatment of Alzheimer Disease
Alexander, G. C., & Karlawish, J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2603 · Cited by 47 · see citing works
Terao, I., Honyashiki, M., & Inoue, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101709 · Cited by 38 · see citing works
Three decades of human monoclonal antibodies: Past, present and future developments
Steinitz, M. O. (2009) · Human Antibodies · doi:10.3233/hab-2009-0196 · Cited by 36 · see citing works
Plasticity in the Working Memory System: Life Span Changes and Response to Injury
Froudist‐Walsh, S., López-Barroso, D., Torres‐Prioris, M. J., Croxson, P. L., & Berthier, M. L. (2017) · The Neuroscientist · doi:10.1177/1073858417717210 · Cited by 31 · see citing works
Precision Medicine for Alzheimer’s Disease Prevention
Berkowitz, C. L., Mosconi, L., Scheyer, O., Rahman, A., Hristov, H., & Isaacson, R. (2018) · Healthcare · doi:10.3390/healthcare6030082 · Cited by 31 · see citing works
Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies
Yang, H., Li, J., Li, X., Ma, L., Hou, M., Zhou, H., & Zhou, R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.927530 · Cited by 30 · see citing works
Shared pathophysiology: Understanding stroke and Alzheimer’s disease
Sriram, S., Mehkri, Y., Quintin, S. S., & Lucke-Wold, B. P. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107306 · Cited by 29 · see citing works
Jean, L., Brimijoin, S., & Vaux, D. J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006230 · Cited by 27 · see citing works
Kshirsagar, S., Alvir, R. V., Hindle, A., Kumar, S., Vijayan, M., Pradeepkiran, J. A., Reddy, A. P., Ramasubramanian, B., & Reddy, P. H. (2022) · Cells · doi:10.3390/cells11040733 · Cited by 26 · see citing works
Delbreil, P., Rabanel, J., Banquy, X., & Brambilla, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114397 · Cited by 25 · see citing works
Aducanumab and the “post-amyloid” era of Alzheimer research?
Musiek, E. S., & Bennett, D. A. (2021) · Neuron · doi:10.1016/j.neuron.2021.09.007 · Cited by 20 · see citing works
Fu, H., Li, J., Du, P., Jin, W., Gao, G., & Cui, D. (2022) · FEBS Letters · doi:10.1002/1873-3468.14549 · Cited by 20 · see citing works
Accelerated Approval of Aducanumab: Where Do We Stand Now?
Levy, H. B. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211050405 · Cited by 19 · see citing works
New Aβ(1–42) ligands from anti-amyloid antibodies: Design, synthesis, and structural interaction
Santoro, A., Grimaldi, M., Buonocore, M., Stillitano, I., Gloria, A., Santin, M., Bobba, F., Saponetti, M. S., Ciaglia, E., & D’Ursi, A. M. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114400 · Cited by 18 · see citing works
Luo, J. J., Wallace, W., & Kusiak, J. W. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120294 · Cited by 17 · see citing works
der Linden, M. V., & der Linden, A. J. V. (2016) · Dementia · doi:10.1177/1471301216657270 · Cited by 16 · see citing works
Khashali, H. A., Ray, R., Coleman, K.-L., Atali, S., Haddad, B., Wareham, J., Guthrie, J. W., Heyl, D., & Evans, H. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810746 · Cited by 13 · see citing works
Deposits of fibrillar Aβ do not cause neuronal loss or ferritin expression in adult rat brain
Bishop, G., & Robinson, S. R. (2003) · Journal of neural transmission · doi:10.1007/s00702-002-0796-2 · Cited by 10 · see citing works
Practical Considerations in the Administration of Aducanumab for the Neurologist
Coerver, K. A., Yu, M. M., D’Abreu, A., Wasserman, M., & Nair, K. V. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001144 · Cited by 10 · see citing works
Alzheimer's disease: Still in need of a cure!
EClinicalMedicine (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101146 · Cited by 9 · see citing works
Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
Ho, G. J., Choo, P. C., Waragai, M., Inoue, S., Masliah, E., & Hashimoto, M. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210021 · Cited by 2 · see citing works
Cerebral microhemorrhage implicated in progression of Alzheimer's disease
Casey, J. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0144 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [10]The Road to Precision Medicine: Eliminating the “One Size Fits” Approach in Alzheimer’s Disease|Elsevier Enhanced Reader Available online: https://reader.elsevier.com/reader/sd/pii/S0753332222007260?token=7271AC75FE6E94A4083968D35ED1989EEE59FC4FA9C399BB5783392DBB8B37BBE68B9D0ABCE4D240E36096116DCE184E&originRegion=eu-west-1&originCreation=20230208093757 (accessed on 8 February 2023)
Cited by
Sorted by citations
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102 · see citing works
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 93 · see citing works
Dighe, S., Jog, S., Momin, M. M., Sawarkar, S. P., & Omri, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010058 · Cited by 93 · see citing works
Shi, T., Shen, S., Shi, Y., Wang, Q., Zhang, G., Lin, J., Chen, J., Bai, F., Zhang, L., Wang, Y., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00989-x · Cited by 87 · see citing works
Exploring cerebral amyloid angiopathy: Insights into pathogenesis, diagnosis, and treatment
Cozza, M., Amadori, L., & Boccardi, V. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120866 · Cited by 84 · see citing works
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works
“It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
BackgroundFołta, J., Rzepka, Z., & Wrześniok, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115177 · Cited by 47 · see citing works
Shen, Y., Zhao, M., Zhao, P., Meng, L., Zhang, Y., Zhang, G., Taishi, Y., & Sun, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1408462 · Cited by 43 · see citing works
Comprehensive Overview of Alzheimer’s Disease: Etiological Insights and Degradation Strategies
Singh, M. K., Shin, Y., Ju, S., Han, S., Kim, S. S., & Kang, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136901 · Cited by 41 · see citing works
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 43 · see citing works
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 37 · see citing works
The neurotransmitter puzzle of Alzheimer's: Dissecting mechanisms and exploring therapeutic horizons
Sharma, M., Pal, P., & Gupta, S. K. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148797 · Cited by 33 · see citing works
Nanoscale drug formulations for the treatment of Alzheimer's disease progression
Liqin, L., He, H., Du, B., & He, Y. (2025) · RSC Advances · doi:10.1039/d4ra08128e · Cited by 37 · see citing works
Osteoporosis and Alzheimer´s disease (or Alzheimer´s disease and Osteoporosis)
Wanionok, N. E., Morel, G. R., & Fernández, J. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102408 · Cited by 30 · see citing works
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 25 · see citing works
Colin, I. M., Szczepanski, L. W., Gérard, A.-C., & Elosegi, J. A. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.16 · Cited by 24 · see citing works
Rakovskaya, A., Erofeev, A., Vinokurov, E. K., Pchitskaya, E. I., Dahl, R. S., & Борисович, Б. И. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813973 · Cited by 19 · see citing works
Lai, G., Wu, H., Yang, K., Hu, K., Zhao, W., Chen, X., Li, J., Haifeng, W., Lv, Z., Xie, G., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s525960 · Cited by 17 · see citing works
SERCA pump as a novel therapeutic target for treating neurodegenerative disorders
Dahl, R. S., & Борисович, Б. И. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150748 · Cited by 17 · see citing works
Targeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy
Jadhav, D., Saraswat, N., Vyawahare, N. S., & Shirode, D. S. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00775-8 · Cited by 14 · see citing works
Aleksandrova, Y. R., Munkuev, A. A., Mozhaitsev, E. S., Суслов, Е. В., Tsypyshev, D. O., Chaprov, K., Бегунов, Р. С., Volcho, K. P., Salakhutdinov, N. F., & Неганова, М. Е. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119743 · Cited by 13 · see citing works
Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2402058 · Cited by 13 · see citing works
Adscheid, S. A., Türeli, A. E., Günday-Türeli, N., & Schneider, M. (2024) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.15.113 · Cited by 13 · see citing works
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 14 · see citing works
Kopeć, K., Koziorowski, D., & Szlufik, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157552 · Cited by 12 · see citing works
Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Sha, S., Ren, L., Xing, X., Guo, W., Wang, Y., Li, Y., Cao, Y., & Qu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00846 · Cited by 16 · see citing works
Bhuiyan, P., Zhang, W., Liang, G., Jiang, B., Vera, R., Chae, R., Kim, K., Louis, L. S., Wang, Y., Liu, J., et al. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10185-7 · Cited by 12 · see citing works
Sokol, D. K., & Lahiri, D. K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1201723 · Cited by 11 · see citing works
Protein aggregation and biomolecular condensation in hypoxic environments (Review)
Li, C., Hao, B., Yang, H., Wang, K., Fan, L., & Xiao, W. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5357 · Cited by 10 · see citing works
Active Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease
Vroom, M. M., & Dodart, J. (2024) · Vaccines · doi:10.3390/vaccines12090973 · Cited by 10 · see citing works
Integrative physiology of skeletal muscle for maintaining cognitive health
Brisendine, M. H., & Drake, J. C. (2025) · The Journal of Physiology · doi:10.1113/jp286748 · Cited by 10 · see citing works
Fiala, M., Hammock, B. D., Hwang, S. H., Whitelegge, J. P., Paul, K. N., Kaczor‐Urbanowicz, K. E., Urbanowicz, A., & Kesari, S. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241305965 · Cited by 9 · see citing works
Hu, M.-H., Zheng, M., Wang, C., Li, Q., Li, J., Zhou, X., Ying, X., Quan, S., Gu, L.-L., & Zhang, X.-Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176305 · Cited by 6 · see citing works
A Potent Sybody Selectively Inhibits α-Synuclein Amyloid Formation by Binding to the P1 Region
Gialama, D., Vadukul, D. M., Thrush, R. J., Radford, S. E., & Aprile, F. A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02408 · Cited by 7 · see citing works
Inflammasomes in Alzheimer’s Progression: Nrf2 as a Preventive Target
López-Hernández, R., de la Torre-Álamo, M. M., García-Bueno, B., Baroja‐Mazo, A., Fenoy, F. J., & Cuevas, S. (2025) · Antioxidants · doi:10.3390/antiox14020121 · Cited by 8 · see citing works
Xu, C., Zhao, L., & Dong, C. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16085 · Cited by 7 · see citing works
Zhou, H., Zhai, J., Gong, H., Fang, R., Zhao, Y., & Luo, W. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.342894 · Cited by 7 · see citing works
Melatonin regulation of phase separation in Neuro-PASC: out-maneuvering Janus-faced amyloids
Loh, D., & Reiter, R. J. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100678 · Cited by 5 · see citing works
Zhou, Q., Cai, J., Qin, F., Liu, J., Li, C., Xiong, W., Wang, Y., Xu, C., & Wu, H. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117542 · Cited by 5 · see citing works
Molecular Mechanisms of Dementia
Cantone, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713027 · Cited by 5 · see citing works
Stone, J., Mitrofanis, J., Johnstone, D. M., & Robinson, S. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231202 · Cited by 4 · see citing works
Heise, N. V., Quast, J., & Csük, R. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100200 · Cited by 4 · see citing works
Vaccine Based Approaches for the Prevention and Treatment of Neurological Disease
Aderinto, N., Abraham, I. C., Olatunji, G. D., Kokori, E., Ashinze, P. T., Babawale, E. A., Alabi, B. O., Opeyemi, O. D., Babalola, A. E., Ayoola, O. I., et al. (2025) · Current Treatment Options in Neurology · doi:10.1007/s11940-025-00827-9 · Cited by 4 · see citing works
Борисович, Б. И. (2026) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041758 · Cited by 4 · see citing works
Bridging the gaps in alzheimer’s disease: a comprehensive review of current and emerging therapies
Mostafa, R. E., & Asaad, G. F. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02151-3 · Cited by 4 · see citing works
Advancing Alzheimer’s care: a novel therapy with lecanemab
Teli, A., & Dhande, P. P. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00747-y · Cited by 2 · see citing works
ACOT7, a candidate and novel serum biomarker of Alzheimer’s disease
Wang, J., Feng, Y., & Sun, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1345668 · Cited by 2 · see citing works
Lee, H., Kim, H., Oh, S. J., Son, Y., Kang, K. J., Nam, K. R., & Choi, J. Y. (2024) · Molecular Imaging and Biology · doi:10.1007/s11307-024-01944-8 · Cited by 2 · see citing works
N-N-Substituted Piperazine, Cmp2, Improves Cognitive and Motor Functions in 5xFAD Mice
Zernov, N., Melenteva, D., Ghamaryan, V., Makichyan, A. T., Hunanyan, L. S., & Александровна, П. Е. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104591 · Cited by 2 · see citing works
Hong, R., Han, J., Dong, F., kalsoom, U.-E., Cao, C., Zhou, A., Wu, Q., & Qu, X. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1798965 · Cited by 1 · see citing works
Friend or foe? Glial–vascular interactions in health and neurodegenerative disease
McQuaid, C., Sewell, M. D. E., & Montagne, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100143 · Cited by 1 · see citing works
Liu, L., Li, J.-H., Bai, Y.-D., Wang, Y., & Bu, X. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00962-0 · Cited by 1 · see citing works
Advances in the treatment of Alzheimer’s disease
Goceroglu, R. T., & Hacımüftüoğlu, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819165 · Cited by 1 · see citing works
Bhati, S. S., & Tanwar, S. S. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00295-0 · Cited by 1 · see citing works
Stationary distribution and extinction of a stochastic Alzheimer's disease model
Lang, R., Tan, Y., & Mu, Y. (2023) · AIMS Mathematics · doi:10.3934/math.20231185 · Cited by 1 · see citing works
Cukkemane, A., Becker, N., Kupreichyk, T., Heise, H., Willbold, D., & Weiergräber, O. H. (2025) · Journal of Structural Biology X · doi:10.1016/j.yjsbx.2025.100128 · Cited by 1 · see citing works
Fiala, M., Hammock, B. D., Hwang, S., Whitelegge, J. P., Kaczor‐Urbanowicz, K. E., Urbanowicz, A., & Kesari, S. (2024) · Preprints.org · doi:10.20944/preprints202405.1741.v1 · Cited by 1 · see citing works
Modern pharmacotherapy of Alzheimer's disease
Holmerová, I., & Nováková, M. (2024) · Klinická farmakologie a farmacie · doi:10.36290/far.2024.010
Current Bioactive Compounds in the Treatment of Alzheimer's Disease
Sharma, P., Pal, R., Sharma, A. K., Kumar, A., & Ashwlayan, V. D. (2024) · Current Bioactive Compounds · doi:10.2174/0115734072340846241025144431
Pharmacochemical Strategies and Advances in Alzheimer's Disease Drug Development
Chen, J. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/qbjryc26
β-Amyloid as a new target to suppress tonic PTH hypersecretion in primary hyperparathyroidismPreprint
Tu, C., Cheng, Z., Szeto, N., Savransky, S., Glinin, T. S., Shoback, D., Sosa, J. A., Vilardaga, J., Koh, J., & Chang, W. (2025) · medRxiv · doi:10.1101/2025.05.27.25328314
Energy constraints and neural strategy transitions in Alzheimer’s: A game-theoretic model
Kareva, I., & Karev, G. P. (2025) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2025.112283
Drugs in clinical trials for Alzheimer's disease
Choi, M., & Adejare, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00009-0
Heo, S., Cha, M., Zhung, W., Kim, J., Keereewan, S., Cho, I., Park, M., Seo, W., Shin, H., Yoon, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69662-z · Cited by 2 · see citing works
Tu, C., Cheng, Z., Szeto, N., Savransky, S., Glinin, T. S., Herberger, A. L., Shoback, D., Sosa, J. A., Vilardaga, J., Koh, J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adz2837
Depression as an early symptom and risk factor of dementia - a narrative review
Permoda-Pachuta, A., Obszański, P., Grad, Z., Futyma-Jędrzejewska, M., Ziemecki, P., & Dominiak, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1786179
A narrative review on preclinical/clinical trials on aducanumab
Goel, A., Garima, G., Jain, P., Bansal, S., Chopra, H., Gupta, S., Kumar, S., Dhanawat, M., & Aggarwal, N. (2026) · Scripta Medica · doi:10.5937/scriptamed57-59386
A mechanistic framework linking the oral microbiome to Alzheimer's disease through neuroinflammation
Evers, M. J. A. P., Krom, B. P., & de Jongh, C. A. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261456324
Polysaccharides targeting organelle network dysfunction in Alzheimer's disease: A review
Yu, X., Gao, P., Yao, Q., Yuan, F., & 经维新 (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.154255
Li, Y., Pu, K., Li, D.-Q., Zhao, Y.-J., Cai, Q.-X., Zhou, X., Li, S.-Q., Chen, Y., Zhou, Z.-J., & Liu, Y. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103376
Surhan, A., Oad, J., Kumar, B., Memon, S. N., Essrani, C., Muhammad, F., Kashif, S. N., Abbas, S. M. I., Ameen, T. B., Sauleh, A., et al. (2026) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-026-01263-5
- Authors
- Wojtunik-Kulesza, K., Rudkowska, M., & Orzeł-Sajdłowska, A.
- Affiliations
- Department of Inorganic Chemistry, Medical University of Lublin, 20-059 Lublin, Poland
- Medical University of Lublin (PL)
- Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lubartowie (PL)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-02-22
- Volume
- 24
- Issue
- 5
- Pages
- 4367
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10002282
- OpenAlex
- W4321598924
- Cited by
- 73
- References
- 86
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 27 · 2023: 13
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- aducanumab, Alzheimer's disease, amyloid-beta, amyloid hypothesis, monoclonal antibodies, drug approval, cognitive impairment, mechanism of action, adverse drug reactions, treatment costs
- MeSH terms
- Alzheimer Disease, Emotions, Humans, Immunoglobulin G, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
